Table 2. Comparison of fetal cardiac malformation rates among different groups.

Group	Vehicle	DEHP	DEHP & Verapamil	Verapamil	P value
No. of dams	10	15	20	10	-
No. of live fetus	78	60	27	72	-
No. of fetal cardiac HE staining	26	20	9	24	-
No. of VSD	0	1	2	0	-
No. of VMCNC	0	6	5	0	-
Fetal cardiac malformation rate (%)	0 (0.0)	7 (35.0)	5 (55.6)	0 (0.0)	<0.001*

DEHP: Di-(2-ethylhexyl)-phthalate; VSD: ventricular septal defect; VMCNC: ventricular myocardium noncompaction.

*Fisher test. Multiple comparisons using the Bonferroni P value adjustment were further conducted and the results demonstrated that the incidence of cardiac malformation was significantly higher in DEHP & verapamil group compared with the DEHP group, the verapamil group and the vehicle group (55.6% vs 35.0%; 55.6% vs 0.0%; 55.6% vs 0.0%; P<0.001), and the incidence of cardiac malformation in DEHP group also had a significant difference in comparison with the verapamil group and the vehicle group (35.0% vs 0.0%; 35.0% vs 0.0%; P<0.001), but there was no significant difference between the verapamil group and the vehicle group (0.0% vs 0.0%)